Pieris Pharmaceuticals, Inc. (PIRS) Analysts See $-0.02 EPS; Chesapeake Asset Management Decreased Its Servicemaster Global Hldgs I (SERV) Position

April 19, 2018 - By Pete Kolinski

ServiceMaster Global Holdings, Inc. (NYSE:SERV) Logo

Chesapeake Asset Management Llc decreased Servicemaster Global Hldgs I (SERV) stake by 36.06% reported in 2017Q4 SEC filing. Chesapeake Asset Management Llc sold 7,004 shares as Servicemaster Global Hldgs I (SERV)’s stock declined 1.48%. The Chesapeake Asset Management Llc holds 12,418 shares with $637,000 value, down from 19,422 last quarter. Servicemaster Global Hldgs I now has $6.99B valuation. The stock decreased 0.88% or $0.46 during the last trading session, reaching $51.63. About 81,197 shares traded. ServiceMaster Global Holdings, Inc. (NYSE:SERV) has risen 26.50% since April 19, 2017 and is uptrending. It has outperformed by 14.95% the S&P500.

Analysts expect Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to report $-0.02 EPS on May, 9.They anticipate $0.17 EPS change or 89.47% from last quarter’s $-0.19 EPS. After having $0.17 EPS previously, Pieris Pharmaceuticals, Inc.’s analysts see -111.76% EPS growth. The stock decreased 1.94% or $0.13 during the last trading session, reaching $6.58. About 165,959 shares traded. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has risen 146.76% since April 19, 2017 and is uptrending. It has outperformed by 135.21% the S&P500.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin drugs. The company has market cap of $354.37 million. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. It currently has negative earnings. The firm primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases.

Among 9 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals had 19 analyst reports since July 22, 2015 according to SRatingsIntel. Roth Capital reinitiated the stock with “Buy” rating in Friday, August 5 report. As per Wednesday, October 18, the company rating was maintained by H.C. Wainwright. The rating was maintained by Roth Capital on Thursday, August 13 with “Buy”. The stock of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) earned “Buy” rating by TH Capital on Wednesday, July 22. The firm has “Buy” rating by Roth Capital given on Wednesday, July 22. H.C. Wainwright maintained Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) on Tuesday, February 13 with “Buy” rating. On Friday, November 10 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was maintained on Monday, March 19 by JMP Securities. The rating was initiated by JMP Securities on Wednesday, August 12 with “Market Outperform”. H.C. Wainwright initiated the stock with “Buy” rating in Tuesday, May 30 report.

Analysts await ServiceMaster Global Holdings, Inc. (NYSE:SERV) to report earnings on April, 26. They expect $0.40 EPS, up 17.65% or $0.06 from last year’s $0.34 per share. SERV’s profit will be $54.14 million for 32.27 P/E if the $0.40 EPS becomes a reality. After $0.35 actual EPS reported by ServiceMaster Global Holdings, Inc. for the previous quarter, Wall Street now forecasts 14.29% EPS growth.

Among 11 analysts covering ServiceMaster (NYSE:SERV), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. ServiceMaster had 30 analyst reports since August 5, 2015 according to SRatingsIntel. As per Thursday, February 15, the company rating was upgraded by Nomura. As per Monday, September 11, the company rating was maintained by Robert W. Baird. The firm earned “Overweight” rating on Monday, October 23 by Morgan Stanley. The rating was maintained by Morgan Stanley on Wednesday, February 28 with “Overweight”. On Wednesday, January 31 the stock rating was maintained by Morgan Stanley with “Overweight”. Instinet upgraded ServiceMaster Global Holdings, Inc. (NYSE:SERV) on Thursday, February 15 to “Buy” rating. The rating was maintained by RBC Capital Markets on Wednesday, August 5 with “Sector Perform”. As per Monday, September 19, the company rating was downgraded by Nomura. Oppenheimer initiated ServiceMaster Global Holdings, Inc. (NYSE:SERV) rating on Tuesday, September 19. Oppenheimer has “Buy” rating and $55.0 target. On Friday, September 15 the stock rating was maintained by RBC Capital Markets with “Buy”.

ServiceMaster Global Holdings, Inc. (NYSE:SERV) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>